Free Trial

Keros Therapeutics (KROS) SEC Filings & 10K Form

Keros Therapeutics logo
$17.03 +0.11 (+0.65%)
(As of 12/20/2024 05:31 PM ET)

Recent Keros Therapeutics SEC Filings

DateFilerForm TypeView
12/12/2024
5:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2024
6:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2024
7:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/08/2024
3:18 PM
CHYUNG YUNG H. (Reporting)
Keros Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
11/06/2024
3:22 PM
Keros Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
7:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2024
7:00 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/03/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/28/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2024
4:06 PM
GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2024
4:01 PM
Keros Therapeutics (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VII LLC (Reporting)
OrbiMed Genesis GP LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:12 PM
Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:02 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
4:15 PM
Keros Therapeutics (Filer)
Form 424B5
06/17/2024
4:17 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
5:07 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
3:10 PM
BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/05/2024
3:11 PM
BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2024
3:15 PM
Farzan Nima (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
GRAY MARY ANN (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Knowles Julius (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Nussbaum Ran (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Kariv Tomer (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Seth Alpna (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
7:03 AM
Keros Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/03/2024
7:00 AM
Keros Therapeutics (Filer)
Form S-3ASR
03/14/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2024
7:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/28/2024
3:02 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/15/2024
7:37 PM
Cooper Simon Peter (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
7:38 PM
Keros Therapeutics (Issuer)
Rovaldi Christopher (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
7:40 PM
Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
7:41 PM
Keros Therapeutics (Issuer)
Seehra Jasbir (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
5:38 PM
ALKEON CAPITAL MANAGEMENT LLC (Filed by)
Keros Therapeutics (Subject)
Form SC 13G/A
This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.
02/09/2024
8:16 AM
FMR LLC (Filed by)
Keros Therapeutics (Subject)
Form SC 13G/A
01/26/2024
4:26 PM
BlackRock Inc. (Filed by)
Keros Therapeutics (Subject)
Form SC 13G/A
01/09/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024
3:43 PM
Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:02 PM
Keros Therapeutics (Filer)
Form 424B5
01/04/2024
3:04 PM
Keros Therapeutics (Subject)
Regnante Keith (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
3:04 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/03/2024
7:04 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:KROS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners